GlobeNewsWire
09 Jun 2026, 16:47 UTC · 15w ago
Verdict
Headline takes no side. We score AB +0.80 across four claims — strongly bullish.
+0.80strongly bullish
More positive than 85% of ticker scores this week
What the story claims
4 claims · scored −1 bearish … +1 bullish
Phase 3 trial data for masitinib in ALS showed a five-year survival rate of 42.3%, significantly exceeding registry benchmarks of approximately 24%.
So whatStrong survival data in a lethal disease with high unmet need is a primary catalyst for drug approval and significant valuation increases for biotech firms.
More positive than 99% of claims this week
Nearly half (49%) of long-term survivors on masitinib maintained a satisfactory quality of life without requiring mechanical assistance.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
More positive than 86% of claims this week
AB Science will present the full survival data from the masitinib clinical program at the ENCALS annual meeting from June 24-26, 2026.
More positive than 63% of claims this week
The company has identified a biomarker that detects masitinib's effect on pro-inflammatory microglia to help identify responsive patients.
More positive than 51% of claims this week
Which stocks this story touches
More positive than 85% of ticker scores this week
The company reported phase 3 trial data indicating clinically relevant survival benefits for its lead compound masitinib in ALS patients.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
−1.3%
Price is moving against the score
$36.19 vs $36.65 close before publication (Jun 8) · not market-adjusted
AB chart →